Megha Padi, Ph.D., of the UA Cancer Center has developed a method for probing the genetic underpinnings of cancer and other diseases, which could lead to better treatments
Category Archives: AZBio News
Built for speed: DNA nanomachines take a (rapid) step forward
Through a process known as strand displacement, a tiny walking device composed of DNA moves across a surface in a cartwheeling motion. The new device performed this feat more rapidly than any DNA walker designed to date.Continue reading
INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial
Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autismContinue reading
LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced, on May 7, 2018, that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. LipimetiX is approximately 60%-owned by Capstone Therapeutics Corp. (OTCQB:CAPS).Continue reading
UA Leading the Way in Precision Medicine
Precision medicine is one of the fastest growing fields of medicine, turning the “one-size fits all” approach of healthcare on its head. Precision medicine is a specialized area of medicine that integrates genetic and genomic knowledge with data on environmental and lifestyle influences to individualize and refine care of patients and populations.Continue reading
HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology
TUCSON, Ariz. and HUNINGUE, France, May 07, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders.Continue reading
C-Path receives COA qualification from FDA for the non-small cell lung cancer
Critical Path Institute’s Patient-Reported Outcome Consortium announces its second clinical outcome assessment qualification from the US Food and Drug AdministrationContinue reading
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
Study will evaluate safety and efficacy of company’s CBD product candidate in rare genetic disease characterized by insatiable appetite in childrenContinue reading
New UA Research Study Aims to Predict and Prevent Deadly Disease in Premature Infants
Study aims to develop the first predictive test to identify and prevent necrotizing enterocolitis, a disease that kills thousands of premature babies each year.Continue reading
